The researchers conjugated anti-CD63 monoclonal antibodies with siRNA using arginine linkers to target the mRNA transcripts of MYC and CTNNB1 genes in human multiple myeloma cells (OPM-2). This evidence concerns the gene MYC and plasma cell myeloma.